Wayne State and Advaita Researchers Can Distinguish Between Aggressive and Less Aggressive Cancer

Wayne State and Advaita Researchers Can Distinguish Between Aggressive and Less Aggressive Cancer

Advaita Bioinformatics is a leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, and disease subtype discovery.

In a breakthrough in cancer diagnosis, a technology developed by a team of researchers from Wayne State University and its biotech startup Advaita Bioinformatics makes it possible to distinguish between aggressive and less aggressive types of disease. Partially funded by a grant from the National Science Foundation and the Robert J. Sokol MD Endowment, this research combines multiple types of data in a single analysis to ultimately reduce the number of patients who do not receive necessary treatments, while also avoiding unnecessary treatments.

This research was sparked by a 2012 report by The New York Times, which revealed that over the previous 30 years, more than 1.4 million women have unnecessarily undergone surgery, chemotherapy or radiation. These treatments cost nearly $23,000 per patient, resulting in a societal cost of $32.2 billion, while there are still patients who may relapse and die because they do not receive necessary treatments.

“It’s critically important that we align each subtype of disease with the appropriate treatment,” said lead researcher Sorin Draghici, Professor of Computer Science, Associate Dean for innovation and entrepreneurship, and CEO of Advaita Bio. “Patients who really need an aggressive treatment will be identified early and treated aggressively, while patients who do not need such treatments will be spared the suffering and cost, for a total savings to the society estimated in tens of billions [of dollars].”

Draghici added that Wayne State’s technology, exclusively licensed by AdvaitaBio can also be used by pharmaceutical companies to distinguish between patients who will and will not respond to a given drug, thus increasing the success of clinical trials and allowing more drugs to reach the market. The framework is also able to integrate multiple types of data including gene expression, DNA methylation, microRNAs and copy number variation data and has been validated on thousands of cancer samples available from the Gene Expression Omnibus, the Broad Institute, The Cancer Genome Atlas and the European Genome-phenome Archive.

This helps makes the drug makers exponentially more efficient in the process of creating drugs. Advaita hopes to take this technology to market later this year.

About Advaita Bioinformatics:

Advaita Bioinformatics is a leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery and integration of multiple data types. Currently, 9 of the top 10 pharma companies rely on Advaita’s state-of-the-art algorithms to solve complex problems. Advaita was founded by Sorin Draghici, a professor at Wayne State University, and provides a suite of advanced analysis software to more that 13,000 registered users worldwide: iPathwayGuide, for functional interpretation of genes and proteins; iVariantGuide, for genetic variant analysis; and iBioGuide, a search engine revealing connections between genes, pathways, SNPs, drugs, and more. Sorin Draghici is also the CEO of Advaita Bioinformatics.

2018-11-12T19:18:40+00:00
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. For further information, visit our Privacy Policy Page. OK